i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial

Официальное название

Integrated Internet-Based Cognitive Behavioural Therapy (i-CBT) and Intravenous Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial

Обзор

Approximately four thousand Canadians die by suicide every year, and suicide is the second leading cause of death in youth and young adults (15-34 years). Most people with depression experience thoughts of suicide and many will also plan and/or attempt suicide at some time in their life. There is an urgent need for new scalable treatments that can effectively reduce suicidality in people with depression. Cognitive behavioural therapy (CBT) reduces suicidal thoughts and behaviours, and can be delivered through the internet (i-CBT) making it more accessible and scalable. However, i-CBT has not been shown to rapidly reduce suicidal thoughts and behaviours (suicidality), such as within 24 hours. IV ketamine on the other hand has been shown to rapidly reduce thoughts of suicide, but not suicidal behaviours. Therefore, combining i-CBT with IV ketamine may be more effective reducing suicidality than i-CBT treatment with a control treatment. The investigators propose a 13-week, multi-site, study that looks at how combining i-CBT and IV ketamine treatment will affect suicidality in individuals with depression who have recently experienced suicidal thoughts and/or behaviours, but have not responded to previous treatment. All 110 participants will receive a weekly session of i-CBT for 13 weeks, but half will be randomly assigned to also receive six IV ketamine treatments or six IV midazolam treatments (control treatment) over the first initial 30 days. The investigators will measure changes in suicidal thoughts and behaviours before drug treatment and at the primary endpoint (i.e.,day 30), and after 3 months (i.e. Day 91) of the starting treatment.

Вмешательства

• Препарат Ketamine hydrochloride
  55 patients will receive ketamine hydrochloride, over six infusions, flexibly dosed between 0.5 mg/kg to 0.85 mg/kg.
• Поведенческое i-CBT (Internet-based Cognitive Behavioural Therapy)
  Each week for 13 weeks, participants will watch an online module that last approximately 45-50 mins each, with homework at the end of each module. Homework is submitted and reviewed by a therapist, who will provide personalized feedback before progression to the next module.
• Препарат Midazolam Hydrochloride
  55 patients will receive midazolam hydrochloride, over six infusions, flexibly dosed between 0.02 mg/kg to 0.035 mg/kg.

Первичные конечные точки

• Suicidality severity using the Columbia-Suicide Severity Rating Scale (C-SSRS) [Срок оценки: 30 Days, up to 91 Days.]

Вторичные конечные точки (12)

• Objective Depressive Symptom Severity using the Montgomery-Asberg Depression Rating Scale (MADRS) [Срок оценки: Day 30, Day 91]
• Subjective Depressive Symptom Severity using the McIntyre and Rosenblat Rapid Response Scale (MARRRS) [Срок оценки: Day 30, Day 91]
• Subjective Depressive Symptom Severity using Quick Inventory for Depressive Symptomatology, Self-Report, 16-item (QIDS-SR-16) [Срок оценки: Day 30, Day 91]
• Symptom Severity and Treatment response using the Clinical Global Impressions Scale (CGI) [Срок оценки: Day 30, Day 91]
• Dissociative Symptom Severity using the Clinician-Administered Dissociative States Scale (CADSS), 23-item [Срок оценки: 30 minutes Post-Infusion]
• Treatment-Emergent Psychiatric Symptoms using the Brief Psychiatric Rating Scale (BPRS) [Срок оценки: 30 minutes Post infusion, Day 30, Day 91]
• Treatment-Emergent Manic Symptoms using the Young Mania Rating Scale (YMRS) [Срок оценки: 30 minutes Post infusion, Day 30, Day 91]
• Mystical Type Experiences using the Mystical Experiences Questionnaire (MEQ) [Срок оценки: 30 minutes Post Infusion, Day 30, Day 91]
• Subjective Wellbeing using the World Health Organization-5 Well-Being Index (WHO-5) [Срок оценки: Day 30, Day 91]
• Impairments in Work and Activities using the World Productivity and Impairment Questionnaire (WPAI) [Срок оценки: Day 30, Day 91]
• Subjective Cognitive Impairment using the Perceived Deficits Questionnaire - Depression - 5-Item (PDQ-5-D) [Срок оценки: Day 30, Day 91]
• Cognitive Function using the Digit Symbol Substitution Test (DSST) [Срок оценки: Day 30, Day 91]

Критерии участия

Критерии включения

• Provide written, voluntary informed consent prior to study enrollment. Substitute decision makers will not be allowed to consent to study on a potential patient's behalf.
• Male or female between the age of 21 to 65, inclusive.
• Meets DSM-5 criteria for Major Depressive Disorder, currently experiencing a Major Depressive Episode (MDE) without psychotic features. Diagnosis will be confirmed using the Mini-International Neuropsychiatric Interview (MINI) conducted by a delegated physician or trained research study staff.
• Must present with a moderate to severe depressive episode, as determined by the MADRS score greater than 21.
• Must be at risk for suicide, operationalized as a response of 'yes' to items 1 or 2 on the Suicidal Ideation subscale or 'yes to any item of the Suicidal Behaviour subscale on the C-SSRS.
• Current MDE has inadequate response to two or more adequate first-line treatment trials for MDD, as per the 2016 CANMAT Depression Guidelines.
• Access to reliable internet for the entire study period and an internet-based device (i.e., a smartphone, laptop, desktop or tablet).
• Must have the ability to speak and read English. This is due to the i-CBT modules only being offered in English presently.

Критерии исключения

• Currently has symptoms of mania or hypomania or mixed state bipolar, as determined by the Young Mania Rating Scale (YMRS) score greater than 12.
• Current symptoms of psychosis or a substance use disorder within the past 3 months. Past history of psychotic features during a mood episode will not be excluded. Other secondary psychiatric comorbidities (e.g. anxiety disorders, trauma related disorders, etc.) will not be excluded.
• Lifetime history of a primary psychotic disorder (including, but not limited to, schizophrenia or schizoaffective disorder).
• Lifetime history of ketamine use disorder.
• History of neurological disorders (including, but not limited to, uncontrolled seizure disorder, history of stroke within past 12 months, major head injuries, aneurysmal vascular disease \[including thoracic and abdominal aorta, intracranial, and peripheral arterial vessels\], arteriovenous malformation, or intracerebral hemorrhage).
• Presence a relative or absolute contraindication to ketamine or midazolam, including a drug allergy, stroke history, uncontrolled hypertension, low or labile blood pressure (as defined by a baseline systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg), recent myocardial infarction within past 12 months, cardiac arrhythmia, severe coronary artery disease, heart failure or moderate to severe hepatic impairment (defined as a Child-Pugh score of B or C) or severe renal impairment (glomerular filtration rate (GFR) < 45 milliliters/min).
• Pregnant or breastfeeding women or women who intend to get pregnant. Patients who are sexually active must agree to use a highly effective contraceptive method.
• Use of prohibited concomitant medications, which includes other forms of ketamine including racemic ketamine and esketamine, benzodiazepines, monoamine oxidase inhibitors, stimulants or medical cannabis of any form. All other medications will be permitted.
• Currently receiving CBT or CBT-related interventions (e.g., Dialectical Behavioural Therapy).
• Changes in medication or non-CBT psychotherapy one month prior to study enrollment.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Четверное слепое

Основная цель

Лечение

Центры проведения

Канада · 1 центр

• Toronto General Hospital — Toronto

Идентификаторы

NCT: NCT06480500 · 21-6000

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗